SPERIMENTAZIONE CLINICA DI UN NUOVO PRODOTTO ANTIMICOTICO: BAY B 5097 (CANESTEN)

Translated title of the contribution: Clinical experimentation with a new anti mycotic: Bayo b 5097 (Canesten)

G. Cavallazzi, A. Cesarani, A. Lasagni

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A new antimycotic, Canesten (Bay b 5097) was administered to 60 outpatients suffering from auricular mycosis. The series includes patients having their first treatment and others having undergone previous therapy with other drugs. In all patients, clinical diagnosis was confirmed by microscopic and cultural examination. The therapeutic programme provided for the instillation of 6-7 drops 2 times a day by the intra aural route until disappearance of the symptoms. As for the outcome, positive results were obtained in 100% of patients, excellent in 75% and good in the remaining 25%. The rapidity of action of Canesten in aural mycotic infections is stressed and its perfect tolerance topically is pointed out.

Translated title of the contributionClinical experimentation with a new anti mycotic: Bayo b 5097 (Canesten)
Original languageItalian
Title of host publicationMinerva Otorinolaringologica
Pages281-294
Number of pages14
Volume25
Edition4
Publication statusPublished - 1975

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Clinical experimentation with a new anti mycotic: Bayo b 5097 (Canesten)'. Together they form a unique fingerprint.

  • Cite this

    Cavallazzi, G., Cesarani, A., & Lasagni, A. (1975). SPERIMENTAZIONE CLINICA DI UN NUOVO PRODOTTO ANTIMICOTICO: BAY B 5097 (CANESTEN). In Minerva Otorinolaringologica (4 ed., Vol. 25, pp. 281-294)